Hepatitis b cure hope fades as early trial ends

NCT ID NCT05345990

Terminated Disease control Sponsor: Hannover Medical School Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This small phase 2 trial tested whether giving hepatitis B antibodies (HBIG) could clear the hepatitis B surface antigen in people with chronic hepatitis B. Only 13 patients were enrolled before the study was terminated. The goal was to see if a 12-week course of injections could make the virus undetectable, potentially reducing the need for long-term medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hepatitis B immunoglobulins (Hepatect and Zutectra)
What this could lead to: If successful, this could point toward a way to clear the hepatitis B surface antigen, potentially reducing the need for lifelong antiviral medication.
What could go wrong: This was a very small, early-phase pilot study with only 13 participants, and it was terminated early. The treatment involves frequent injections and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

Hannover Medical School, Department for Gastroenterology, Hepatology and Endocrinology

Hanover, Lower Saxony, 30625, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.